Read by QxMD icon Read

Psoriatic AND arthritis

M K Nisar
INTRODUCTION: Early arthritis clinics (EACs) have been well established since 1980s. Most of the data for their effectiveness comes from rheumatoid arthritis (RA) management and is largely limited to process outcomes. There is little evidence that such clinics improve clinical outcomes particularly for psoriatic arthritis (PsA). We examined whether EACs provide better outcomes irrespective of final arthritis diagnosis. METHODS: A 52-week prospective observational study of all inflammatory arthritis patients presenting to early arthritis service at our secondary care hospital in 2016 was undertaken...
February 19, 2019: Rheumatology International
Remy A Pollock, Laila Zaman, Vinod Chandran, Dafna D Gladman
Psoriasis and its associated inflammatory arthritis, psoriatic arthritis (PsA), have a clear heritable component, but a large proportion of the heritable risk remains unexplained by gene sequence variation. This study aimed to determine if epigenetic factors contribute to the missing heritability in psoriatic disease. DNA methylation profiling was performed on sperm cells from 23 probands with psoriasis without PsA (PsC), 13 PsA probands, and 18 unaffected controls. Differentially methylated CpGs and regions (DMRs) were identified and validated by pyrosequencing...
2019: PloS One
T P Afra, T Muhammed Razmi, Sunil Dogra
Apremilast, an orally administered small molecule inhibitor of phosphodiesterase 4 (PDE4), has been licensed by the US Food and Drug Administration for the management of active psoriatic arthritis (March 21, 2014) and moderate to severe plaque psoriasis (September 23, 2014). It has got approval from Drug Controller General of India for marketing in India in 2017. The drug has drawn much attention from the practising dermatologists for its commendable safety profile and prescription convenience. Introduced initially as an orally administered small molecule in psoriasis patients, the drug has now been used in various other indications as evident by the recent surge in literature for its off-label uses...
January 2019: Indian Dermatology Online Journal
L Degli Esposti, V Perrone, D Sangiorgi, D Alessandrini, S Buda, F Cantini, E Mazzini, C Toma, F De Solda
Purpose: The purpose of this study was to analyze the therapeutic strategies and estimate the health care resource consumption in patients with psoriatic arthritis (PsA). Patients and methods: An observational retrospective cohort analysis of administrative databases of six Italian Local Health Units was performed. Patients ≥18 years with a hospitalization discharge diagnosis of PsA (International Classification of Diseases, Ninth Revision code: 696.0) or exemption code (045...
2019: Patient Preference and Adherence
Di Long, Yongjian Chen, Haijing Wu, Ming Zhao, Qianjin Lu
Interleukin-21 (IL-21), an autocrine cytokine predominantly produced by follicular helper T (Tfh) and T helper 17 (Th17) cells, has been proven to play an important role in the immune system, for example, by promoting proliferation and the development of Tfh and Th17 cells, balancing helper T cell subsets, inducing B cell generation and differentiation into plasma cells, and enhancing the production of immunoglobulin. These effects are mainly mediated by activation of the JAK/STAT, MAPK and PI3K pathways...
February 14, 2019: Journal of Autoimmunity
Giuseppina Abignano, Nafisa Fadl, Mira Merashli, Claire Vandevelde, Jane Freeston, Dennis McGonagle, Helena Marzo-Ortega Lms
No abstract text is available yet for this article.
February 13, 2019: Journal of the American Academy of Dermatology
Arthur Kavanaugh, M Elaine Husni, Diane D Harrison, Lilianne Kim, Kim Hung Lo, Lenore Noonan, Elizabeth C Hsia
OBJECTIVE: Evaluate effects of intravenous (IV) golimumab (GOL) on radiographic progression in psoriatic arthritis (PsA). METHODS: This phase III, randomized, double-blind, placebo-controlled trial (GO-VIBRANT) randomized patients with active PsA to receive IV placebo (n = 239) or IV GOL 2 mg/kg (n = 241) at weeks 0, 4, 12, and 20. Radiographic progression (controlled secondary endpoint) was evaluated as change from baseline at Week 24 in PsA-modified total Sharp/van der Heijde scores (SvdH)...
February 15, 2019: Journal of Rheumatology
Alí Duarte-García, Ying Ying Leung, Laura C Coates, Dorcas Beaton, Robin Christensen, Ethan T Craig, Maarten de Wit, Lihi Eder, Lara Fallon, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Richard Holland, Chris Lindsay, Lara Maxwell, Philip Mease, Ana Maria Orbai, Bev Shea, Vibeke Strand, Douglas J Veale, William Tillett, Alexis Ogdie
OBJECTIVE: The psoriatic arthritis (PsA) core domain set for randomized controlled trials (RCTs) and longitudinal observational studies (LOS) has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting approaches to seek endorsement of the 66/68-swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set...
February 15, 2019: Journal of Rheumatology
Mitsumasa Kishimoto, Kazuki Yoshida, Naomi Ichikawa, Hisashi Inoue, Yuko Kaneko, Taku Kawasaki, Kazuo Matsui, Mitsuhiro Morita, Masei Suda, Kurisu Tada, Naoho Takizawa, Naoto Tamura, Atsuo Taniguchi, Yoshinori Taniguchi, Shigeyoshi Tsuji, Yoichiro Haji, Ryo Rokutanda, Haruyuki Yanaoka, Peter P Cheung, Jieruo Gu, Tae-Hwan Kim, Shue-Fen Luo, Masato Okada, Clementina López Medina, Anna Molto, Maxime Dougados, Shigeto Kobayashi, Désirée van der Heijde, Tetsuya Tomita
OBJECTIVE: To delineate clinical characteristics of patients with spondyloarthritis (SpA) in Japan in comparison to other areas of the world. METHODS: Using the ASAS-COMOSPA (Assessment of Spondyloarthritis international Society-COMOrbidities in SPondyloArthritis) data, an international cross-sectional observational study of patients with SpA, we analyzed information on demographics, disease characteristics, comorbidities, and risk factors. Patients were classified by region: Japan, other Asian countries (China, Singapore, South Korea, Taiwan), and non-Asian countries (Europe, the Americas, Africa)...
February 15, 2019: Journal of Rheumatology
Kieran Murray, Louise Moore, Fionnuala McAuliffe, Douglas J Veale
No abstract text is available yet for this article.
February 15, 2019: Annals of the Rheumatic Diseases
Fabiola Atzeni, Piercarlo Sarzi-Puttini, Marco Sebastiani, Valentina Panetta, Fausto Salaffi, Florenzo Iannone, Antonio Carletto, Rosario Foti, Elisa Gremese, Marcello Govoni, Antonio Marchesoni, Ennio Favalli, Roberto Gorla, Roberta Ramonda, Gianfranco Ferraccioli, Giovanni Lapadula
OBJECTIVES: To determine the incidence of serious infections (SIs) among the spondyloarthropathy (SpA) patients from the "Gruppo Italiano per lo Studio delle Early Arthritis" (GISEA) registry and treated with tumour necrosis factor (TNF) inhibitors (TNFIs), and to identify the factors associated with the development of the infections. METHODS: This observational study on 3321 GISEA-registered SpA patients collected real-world demographic and clinical data relating to their biological drug treatments...
February 11, 2019: Clinical and Experimental Rheumatology
Sibel Bakirci, Dilek Solmaz, Noura Al Osaimi, Ediz Dalkilic, Meryem Can, Abdulsamet Erden, Cem Ozisler, Muhammet Cinar, Levent Kilic, Adem Küçük, Ahmet Omma, Fatih Yildiz, Atalay Doğru, Abdurrahman Tufan, Serpil Ergulu Esmen, Servet Akar, Umut Kalyoncu, Sibel Zehra Aydin
OBJECTIVES: Minimal disease activity (MDA) is an important target in patients with psoriatic arthritis (PsA), however it is also criticised for having a low threshold for patient reported outcomes (PRO).The aim of the study was to assess the prevalence of MDA and its components in patients with PsA and to evaluate disease characteristics and patterns in patients with or without MDA (MDA+ or MDA-). METHODS: PsArt-ID (Psoriatic Arthritis-International Database) is a prospective, multicentre web-based registry...
February 11, 2019: Clinical and Experimental Rheumatology
Zohra Layegh, Jill Ruwaard, Renske C F Hebing, Merel J L' Ami, Wilfred van der Weele, Mike T Nurmohamed, Charlotte Krieckaert, Gertjan Wolbink
OBJECTIVES: To evaluate the transition from reference infliximab Remicade to biosimilar Remsima in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA). METHODS: Patients were informed through a letter about the transition to a biosimilar and were subsequently contacted for possible additional questions and whether they agreed upon the transition. Once agreed, Remsima was administered at the same dosage and interval as previous treatment with Remicade...
February 14, 2019: International Journal of Rheumatic Diseases
Volkan Aydin, Ahmet Akici, Fatma Isli, Mesil Aksoy, Mehtap Aydin, Hakki Gursoz
WHAT IS KNOWN AND OBJECTIVE: Anti-tumour necrosis factor-alpha (anti-TNF-α) therapy is known to raise the risk of granulomatous infections, leading to development of risk management strategies at national or global level. This study aimed to determine the relative risk (RR) of tuberculosis (TB) due to anti-TNF-α usage in patients with rheumatologic diseases (RDs) in a nationwide basis. METHOD: This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without anti-TNF-α agents, as registered in the national prescription information system between years 2013 and 2015...
February 14, 2019: Journal of Clinical Pharmacy and Therapeutics
Christoph M Schempp, Franziska Schauer, Christian K Huhn, Nils Venhoff, Stephanie Finzel
Syndromes associated with concurrent skin and joint inflammation frequently pose a therapeutic challenge for both dermatologists and rheumatologists. In part 1 of this review, we discussed psoriatic arthritis as well as the autoinflammatory disorders SAPHO syndrome, Still's disease and Behçet's disease. Part 2 will address rheumatoid arthritis, reactive arthritis, Reiter's syndrome and Lyme borreliosis. In addition, we will discuss dermatomyositis and lupus erythematosus, two common autoimmune disorders that frequently present with both cutaneous and joint involvement...
February 2019: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
Guro L Goll, Kristin K Jørgensen, Joe Sexton, Inge C Olsen, Nils Bolstad, Espen A Haavardsholm, Knut Ea Lundin, Kåre S Tveit, Merete Lorentzen, Ingrid P Berset, Bjørg Ts Fevang, Synøve Kalstad, Kristin Ryggen, David J Warren, Rolf A Klaasen, Øivind Asak, Somyeh Baigh, Ingrid M Blomgren, Øystein Brenna, Trude J Bruun, Katrine Dvergsnes, Svein O Frigstad, Inger M Hansen, Ingvild S H Hatten, Gert Huppertz-Hauss, Magne Henriksen, Sunniva S Hoie, Jan Krogh, Irina P Midtgard, Pawel Mielnik, Bjørn Moum, Geir Noraberg, Armin Poyan, Ulf Prestegård, Haroon Ur Rashid, Eldri K Strand, Kristine Skjetne, Kathrine A Seeberg, Roald Torp, Carl M Ystrøm, Cecilia Vold, Camilla C Zettel, Kenneth Waksvik, Bjørn Gulbrandsen, Jon Hagfors, Cato Mørk, Jørgen Jahnsen, Tore K Kvien
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double blind, non-inferiority, government funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment with infliximab originator. The NOR-SWITCH extension trial aimed to assess efficacy, safety and immunogenicity in patients on CT-P13 throughout the 78-week study period (maintenance group) vs patients switched to CT-P13 at week 52 (switch group)...
February 14, 2019: Journal of Internal Medicine
Basant Elnady, Nashwa K El Shaarawy, Noha Mohammed Dawoud, Tohamy Elkhouly, Dalia El-Sayed Desouky, Eman Nabil ElShafey, Mohamed S El Husseiny, Johannes J Rasker
OBJECTIVE: To evaluate ultrasonographic subclinical inflammatory synovitis and enthesitis in psoriasis patients, without clinical arthritis or enthesitis compared with healthy controls, with a 2-year follow-up to study the associated incidence of psoriatic arthritis (PsA). METHODS: A total of 109 consecutive psoriasis vulgaris patients without clinical signs of PsA and 90 healthy controls were included from two tertiary medical centers. Subjects underwent dermatological examination, PASI score evaluation for severity of psoriasis, musculoskeletal examination using 68/66 joints count for tenderness and swollen joints...
February 12, 2019: Clinical Rheumatology
Sabine Löhr, Arif B Ekici, Steffen Uebe, Christian Büttner, Michaela Köhm, Frank Behrens, Beate Böhm, Michael Sticherling, Georg Schett, David Simon, Rotraut Mössner, Ali Nimeh, Vinzenz Oji, Gunter Assmann, Jürgen Rech, Rikard Holmdahl, Harald Burkhardt, André Reis, Ulrike Hüffmeier
No abstract text is available yet for this article.
February 7, 2019: Rheumatology
Philip J Mease, Dafna D Gladman, David H Collier, Christopher T Ritchlin, Philip S Helliwell, Lyrica Liu, Gregory Kricorian, James B Chung
OBJECTIVE: To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept in patients with psoriatic arthritis (PsA). METHODS: In this double-blind study, 851 PsA patients were randomized to: oral methotrexate 20mg plus placebo weekly (N=284), etanercept 50mg plus placebo weekly (N=284), or etanercept 50mg plus oral methotrexate 20mg weekly (combination therapy; N=283). American College of Rheumatology (ACR)20 response and Minimal Disease Activity (MDA) response at week 24 were the primary and key secondary endpoints, respectively...
February 12, 2019: Arthritis & Rheumatology
Vinh Ngo Minh, Van Bui Thi, Tro Chau Van, Trai Nguyen Ngoc, Anh Tran Ngoc, Em Dang Van, Marco Gandolfi, Francesca Satolli, Claudio Feliciani, Michael Tirant, Aleksandra Vojvodic, Torello Lotti
We conducted a prospective, cross-sectional study at Ho Chi Minh City Hospital of Dermato Venereology from January 2016 to March 2017 in 40 psoriatic arthritis (PsA) patients to evaluate the disease progression and therapeutic burden about the HLA patterns. Based upon our results, PsA with HLA-B27 (+) had a threat of severe arthritis. PsA with HLA-Cw06 (+) had a higher risk of earlier onset and shorter duration for plaque psoriasis to transform into PsA. HLA-DR7 (+) in PsA delayed the time for conversion from plaque psoriasis into PsA...
January 30, 2019: Open Access Macedonian Journal of Medical Sciences
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"